bioRxivMicrobiologyPreprint
Probiotic Stirred Yogurt Mediated the Prevention of Metabolic Dysfunction-Associated Steatotic Liver Disease in Rats
Mohamed S. Sallam, Eman H. Ayad, Saeid M. Darwish, Mohamed A. Gomaa, Marwa G. Allam
Abstract
Metabolic dysfunction-associated Steatotic liver disease (MASLD) is the most common cause of chronic liver diseases and it is greatly influenced by an unhealthy and sedentary lifestyle. Studies have encouraged the use of probiotics as promising and safe therapeutic approach. This research examined the probiotic potential of eleven bacterial strains, with Lactococcus rhamnosus, Lactobacillus plantarum, Lactobacillus acidophilus, and Bifidobacterium lactis being selected for yogurt production, either as single strain or in combination. The probiotic-rich yogurt samples were then tested for their ability to prevent the development of MASLD in vivo using a rat model fed a high-fat diet (HFD). Key biomarkers such as cholesterol, triglycerides, low-density lipoproteins (LDL), high-density lipoproteins (HDL), glucose, insulin, alanine transaminase (ALT), and albumin levels were measured. Besides, liver histology and the microbial analysis of the small intestine were examined. The sensory revealed that yogurt containing the probiotic mixture (T5) had improved taste and flavor. The probiotic mixing revealed a potentiated effect in preventing MASLD. T5 significantly lowered cholesterol (85.1 mg/dl), triglycerides (122.3 mg/dl), LDL (25.8 mg/dl), glucose (28.6 mg/dl), insulin (0.84 IU/ml), and ALT (36.9 U/L) levels in the rats to close values as in the control. Additionally, the treated rats showed restored albumin and HDL levels compared to those treated with yogurt containing a single probiotic strain. The ameliorating effects of T5 were also evident in the liver histology, with normal hepatocytes and minimal fat deposits. Furthermore, the probiotic mixture in T5 improved the liver-gut axis by reducing the coliform and staphylococcus count in the small intestine. Consequently, the probiotic mixture could be a promising therapeutic agent for MASLD and the ultimate goal of this project is to develop a functional food product that can provide an alternative cost-effective approach for the management of MASLD in Egyptian population.
- organism: rat
- assay: proteomics
- assay: metabolomics
- research focus: metabolism & bioenergetics
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Liraglutide exerts protective effects on MASLD independently of lipophagy, and the combination with kombucha presents no additional advantage
Jenifer Souza de Almeida, Sandra Andreotti, … Carla Roberta de Oliveira Carvalho·Brazilian Journal of Health ReviewPeer-reviewed·Jan 19, 2026
- A Host Enzyme Reduces Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Inactivating Intestinal Lipopolysaccharide
Zhiyan Wang, Nore Ojogun, … Mingfang Lu·eLifePeer-reviewed·Oct 14, 2024
- Prebiotic xylo-oligosaccharides for alleviation of hepatic steatosis: Results from a four-month dietary intervention and determinants of response
Jukka E. Hintikka, Perttu Permi, … Satu Pekkala·npj gut and liver.Peer-reviewed·May 6, 2026
- Gut microbiota and bile acids changes in MASLD mice model with hepatic PLD1 knockout
Yushang Zhao, Huan Wang, … Linlin Cao·Acta Biochimica et Biophysica SinicaPeer-reviewed·Sep 24, 2025
- Gut microbial phenylalanine metabolism contributes to MASLD in a dietary protein-dependent manner
Yi Rou Bah, Dayang Nurul Asyiqin Binte Mustafa, … Kazuyuki Kasahara·bioRxiv·Sep 28, 2026
- Bacterial metabolic signatures in MASLD predicted through gene-centric studies in stool metagenomes
Juan Manuel Medina-Méndez, Paula Iruzubieta, … Fernando de la Cruz·BMC MicrobiologyPeer-reviewed·Dec 18, 2025